Phase 3 N=640 Clinical Evaluation of Patient Preoperative Prep
Surgical Skin Preparation
Primary: Bacterial Reduction — 4.04; 4.01; 1.60 log10 cfu/cm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,146 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
Cholera
Primary: Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and B — 9220; 10034 Geometric Mean Titer
Phase 3 N=620 A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Primary: Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase — 31.9; 37.5 Percentage of…
Phase 3 N=211 Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block
Axillary Nerve Block
Primary: Percentage of Participants With Successful Block for Distal Upper Limb Surgeries — 96; 97 Participants
Phase 3 N=125 Vitamin C and Septic Shock
Septic Shock · Sepsis
Primary: Number of Participants With ICU Mortality — 20; 14 Participants
Phase 3 N=40 Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis
Arthritis
Primary: Numeric Pain Rating Scale — 1.7; 2.4; 3.2 units on a scale — p=0.6
Phase 3 N=84 A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation
Lip Augmentation
Primary: Change From Baseline in Lip Fullness Grading Scale — .82 score on a scale
Phase 3 N=326 Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
Pulmonary Hypertension · Interstitial Lung Disease · Combined Pulmonary Fibrosis and Emphysema
Primary: Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 — -9.0; 6.0 meters — p=0.0043
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
Phase 3 N=127 A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Hepatitis C Virus (HCV)
Primary: Steady-state Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Glecaprevir — 4790; 7870; 6860; 7520 ng*h/mL
Phase 3 N=327 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16 — 65.6; 73.8 percentage of participants
Phase 3 N=86 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Recurrent Pericarditis
Primary: Time to Pericarditis Recurrence in the RW Period — NA; 8.6 weeks — p=<0.0001
Phase 3 N=399 Trial of Extended Release Bupivacaine for Pain Relief After Surgery
Post Operative Pain
Primary: Pain Intensity on Movement From 0-48 Hours Post-Treatment — 5.55; 5.87 score on a scale — p=0.124
Phase 3 N=71 StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
Burn, Thermal
Primary: Percent Area of Treatment Sites Requiring Autografting by Month 3 — 4.33; 102.10 percentage of treatment sites — p=<0.0001
Phase 3 N=196 Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
Gastric Cancer · Obesity
Primary: Number of Retrieved Lymph Nodes Per Participant — 44.6; 41.5; 49.2; 39.2 lymph nodes